Bioadaptives (BDPT) Net Income towards Common Stockholders (2019 - 2025)
Historic Net Income towards Common Stockholders for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$379502.0.
- Bioadaptives' Net Income towards Common Stockholders fell 90800.02% to -$379502.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 16846.43%. This contributed to the annual value of -$694068.0 for FY2024, which is 7714.31% down from last year.
- Latest data reveals that Bioadaptives reported Net Income towards Common Stockholders of -$379502.0 as of Q3 2025, which was down 90800.02% from -$157914.0 recorded in Q2 2025.
- In the past 5 years, Bioadaptives' Net Income towards Common Stockholders registered a high of -$34516.0 during Q3 2021, and its lowest value of -$491903.0 during Q1 2021.
- Its 5-year average for Net Income towards Common Stockholders is -$204103.7, with a median of -$171151.0 in 2022.
- In the last 5 years, Bioadaptives' Net Income towards Common Stockholders skyrocketed by 8092.29% in 2023 and then crashed by 90800.02% in 2025.
- Quarter analysis of 5 years shows Bioadaptives' Net Income towards Common Stockholders stood at -$308336.0 in 2021, then skyrocketed by 62.1% to -$116851.0 in 2022, then grew by 13.79% to -$100734.0 in 2023, then plummeted by 244.51% to -$347036.0 in 2024, then dropped by 9.36% to -$379502.0 in 2025.
- Its Net Income towards Common Stockholders was -$379502.0 in Q3 2025, compared to -$157914.0 in Q2 2025 and -$258795.0 in Q1 2025.